MedDevNews, Q4 2022
Market indicators were generally positive in Q4 2022, despite recession concerns. The number of financings, OEM M&A transactions, and CMO M&A transactions increased to highs for the year. Additionally, disclosed value for these deals remained substantial in the case of OEM M&A hitting a new high. Public market returns were mostly negative but improved relative to Q3, with two verticals -CMO and Organ & Tissue Transplant -showing positive returns. CMOs were a clear winner in Q4, doubling in the number of M&A transactions relative to Q3.
